Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts

British Journal of Cancer

Volumn 83, Issue 7, 2000, Pages 921-927

  Kolfschoten, G M ^a   Hulscher, T M ^a   Pinedo, H M ^a   Boven, E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Drug resistance; LRP; Ovarian cancer xenografts; S phase fraction

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE S PHASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; TUMOR XENOGRAFT;

EID: 0033830420     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1373     Document Type: Article

References (42)

1. Drug resistance-associated markers P-glycoprotein, multidrug resistance- associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma
2. Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line
3. Expression of a human multidrug resistance gene in ovarian carcinomas
4. Phase II preclinical drug screening in human tumour xenografts: A first European multicenter collaborative study
5. Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy
6. Pharmacological characterization of multidrug resistant MRP-transfected human turmour cells
7. Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma
8. 165 expression differentially affects the growth inhibition induced by anticancer agents in human ovarian cancer xenografts
9. Identification of novel drug resistance-associated proteins by a panel of rat monoclonal antibodies
10. The relationship between turnout glutathione concentration, glutathione S-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patients
11. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung
12. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines
13. Experimental model systems of ovarian cancer: Applications to the design and evaluation of new treatment approaches
14. Glutathione-associated cisdiamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance
15. How does the MRP/GS-X pump export doxorubicin?
16. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma
17. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines
18. The influence of BIBW22BS, a dipyridamole derivative, on the antiproliferative effects of 5-fluorouracil, methotrexate and gemcitabine in vitro and in human tumour xenografts
19. Mechanisms of drug resistance in ovarian cancer
20. MDR 1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumours
21. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system
22. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRPI), in human cancer cell lines
23. Preclinical phase II studies in human tumour xenografts: A European multicenter follow-up study
24. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene
25. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia
26. Biology of the multidrug resistance-associated protein, MRP
27. Human ovarian cancer xenografts in nude mice: Characterization and analysis of antigen expression
28. Current status of systemic chemotherapy in the treatment of advanced ovarian cancer with emphasis on CHAP-5
29. Cellular resistance to anthracyclines
30. Quantitative analysis of MDR 1 (multidrug resistance) gene expression in human tumours by polymerase chain reaction
31. P-glycoprotein - A marker of cancer-cell behavior
32. Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma
33. Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy
34. The role of the MDR 1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo
35. Expression of P-glycoprotein in epithelial ovarian cancer: Evaluation as a marker of multidrug resistance
36. The drug resistance-related protein LRP is the human major vault protein
37. Measurement and prediction of the short-term response of soil tissue sarcomas to chemotherapy
38. Glutathione and drug resistance
39. Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma. II. DNA flow cytometry changes during chemotherapy, tumor regression, and short-term follow-up
40. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy
41. Analysis of the expression of MRP, the gene for a new putative transmembmne drug transporter, in human multidrug resistant lung cancer cell lines
42. Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line